Potential Therapeutic and Pharmacological Strategies for SARS-CoV2

Overview

Journal J Pharm Investig

Publisher Springer

Specialty Chemistry

Date 2021 Mar 10

PMID 33688448

Citations 12

Authors

Doaa A Ghareeb

Samar R Saleh

Mohammed S Nofal

Mohamed M Y Kaddah

Salma F Hassan

Inas K Seif

Sally A El-Zahaby

Shaimaa M Khedr

Marwa Y Kenawy

Aliaa A Masoud

Salma A Soudi

Ahmed A Sobhy

Jaillan G Sery

Miral G Abd El-Wahab

Alshimaa A Abd Elmoneam

Abdulaziz Mohsen Al-Mahallawi

Maha A El-Demellawy

Affiliations

Soon will be listed here.

Abstract

Background: At the end of 2019, the new Coronavirus disease 2019 (COVID-19) strain causing severe acute respiratory syndrome swept the world. From November 2019 till February 2021, this virus infected nearly 104 million, with more than two million deaths and about 25 million active cases. This has prompted scientists to discover effective drugs to combat this pandemic.

Area Covered: Drug repurposing is the magic bullet for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Therefore, several drugs have been investigated in silico, in vitro, as well as through human trials such as anti-SARS-CoV2 agents, or to prevent the complications resulting from the virus. In this review, the mechanisms of action of different therapeutic strategies are summarized. According to the WHO, different classes of drugs can be used, including anti-malarial, antiviral, anti-inflammatory, and anti-coagulant drugs, as well as angiotensin-converting enzyme inhibitors, antibiotics, vitamins, zinc, neutralizing antibodies, and convalescent plasma therapy. Recently, there are some vaccines which are approved against SARS-CoV2.

Expert Opinion: A complete understanding of the structure and function of all viral proteins that play a fundamental role in viral infection, which contribute to the therapeutic intervention and the development of vaccine in order to reduce the mortality rate.

Supplementary Information: The online version contains supplementary material available at 10.1007/s40005-021-00520-4.

Citing Articles

Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.

Dhama K, Nainu F, Frediansyah A, Yatoo M, Mohapatra R, Chakraborty S J Infect Public Health. 2022; 16(1):4-14.

PMID: 36446204 PMC: 9675435. DOI: 10.1016/j.jiph.2022.11.024.

ZnO-chlorogenic acid nanostructured complex inhibits Covid-19 pathogenesis and increases hydroxychloroquine efficacy.

Abomughaid M, Nofal M, Ghaleb K, Seadawy M, AbdEl-Wahab M, Hegazy A J King Saud Univ Sci. 2022; 34(8):102296.

PMID: 36062198 PMC: 9425706. DOI: 10.1016/j.jksus.2022.102296.

Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.

Li X, Zhang Y, He L, Si J, Qiu S, He Y Int J Biol Sci. 2022; 18(5):1865-1877.

PMID: 35342348 PMC: 8935217. DOI: 10.7150/ijbs.66369.

Effects of 1α,25-dihydroxyvitamin D on the pharmacokinetics and biodistribution of ergothioneine, an endogenous organic cation/carnitine transporter 1 substrate, in rats.

Vo D, Nguyen T, Maeng H J Pharm Investig. 2022; 52(3):341-351.

PMID: 35291466 PMC: 8911105. DOI: 10.1007/s40005-022-00563-1.

COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.

Dhama K, Dhawan M, Tiwari R, Emran T, Mitra S, Rabaan A Hum Vaccin Immunother. 2022; 18(5):2045853.

PMID: 35258416 PMC: 8935456. DOI: 10.1080/21645515.2022.2045853.

References

Kitchens C . Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Hematology Am Soc Hematol Educ Program. 2009; :240-6. DOI: 10.1182/asheducation-2009.1.240. View

McCartney D, Byrne D . Optimisation of Vitamin D Status for Enhanced Immuno-protection Against Covid-19. Ir Med J. 2020; 113(4):58. View

Ghaffari H, Tavakoli A, Moradi A, Tabarraei A, Bokharaei-Salim F, Zahmatkeshan M . Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine. J Biomed Sci. 2019; 26(1):70. PMC: 6734352. DOI: 10.1186/s12929-019-0563-4. View

Overlack A . ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996; 15(1):72-8. DOI: 10.2165/00002018-199615010-00006. View

Roback J, Guarner J . Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020; 323(16):1561-1562. DOI: 10.1001/jama.2020.4940. View

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

Mishra Y, Adelung R, Rohl C, Shukla D, Spors F, Tiwari V . Virostatic potential of micro-nano filopodia-like ZnO structures against herpes simplex virus-1. Antiviral Res. 2011; 92(2):305-12. PMC: 4148000. DOI: 10.1016/j.antiviral.2011.08.017. View

Chandwani A, Shuter J . Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2009; 4(5):1023-33. PMC: 2621403. DOI: 10.2147/tcrm.s3285. View

Meydani S, Leka L, Fine B, Dallal G, Keusch G, Fiatarone Singh M . Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial. JAMA. 2004; 292(7):828-36. PMC: 2377357. DOI: 10.1001/jama.292.7.828. View

10.

Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K . Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. PMC: 7127386. DOI: 10.1016/j.antiviral.2020.104786. View

11.

Zheng J, Zhou R, Chen F, Tang G, Wu K, Li F . Incidence, clinical course and risk factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: A prospective cohort study. PLoS Negl Trop Dis. 2020; 14(8):e0008648. PMC: 7505432. DOI: 10.1371/journal.pntd.0008648. View

12.

Simmons G, Zmora P, Gierer S, Heurich A, Pohlmann S . Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res. 2013; 100(3):605-14. PMC: 3889862. DOI: 10.1016/j.antiviral.2013.09.028. View

13.

Zhang C, Wu Z, Li J, Zhao H, Wang G . Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55(5):105954. PMC: 7118634. DOI: 10.1016/j.ijantimicag.2020.105954. View

14.

Gozzetti A, Capochiani E, Bocchia M . The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19. Leukemia. 2020; 34(10):2815-2816. PMC: 7467142. DOI: 10.1038/s41375-020-01038-8. View

15.

HARDAWAY R, Harke H, Tyroch A, Williams C, Vazquez Y, Krause G . Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. Am Surg. 2001; 67(4):377-82. View

16.

Lazarczyk M, Favre M . Role of Zn2+ ions in host-virus interactions. J Virol. 2008; 82(23):11486-94. PMC: 2583646. DOI: 10.1128/JVI.01314-08. View

17.

Andreone P, Fiorino S, Cursaro C, Gramenzi A, Margotti M, Di Giammarino L . Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. Antiviral Res. 2001; 49(2):75-81. DOI: 10.1016/s0166-3542(00)00141-8. View

18.

Hemila H, Louhiala P . Vitamin C may affect lung infections. J R Soc Med. 2007; 100(11):495-8. PMC: 2099400. DOI: 10.1177/014107680710001109. View

19.

Fang M, Chen J, Xu X, Yang P, Hildebrand H . Antibacterial activities of inorganic agents on six bacteria associated with oral infections by two susceptibility tests. Int J Antimicrob Agents. 2006; 27(6):513-7. DOI: 10.1016/j.ijantimicag.2006.01.008. View

20.

Lippi G, Plebani M, Henry B . Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020; 506:145-148. PMC: 7102663. DOI: 10.1016/j.cca.2020.03.022. View